


Neoplasms

Background

The changes to ICD-10-AM Chapter 2 *Neoplasms*, ACHI and the ACS have occurred as a result of public submissions and coding queries that were received.

- Advancements in delivery methods and products available for pharmacotherapy for multiple conditions have prompted some of these changes. This includes products such as Albumex, prothrombin X, and the administration of non blood product such as Haemaccel.
- ACCD also identified the need for a new ACHI code for the removal of a brachytherapy applicator of the prostate.
- The guidelines for oral/transmucosal pharmacotherapy for the treatment of malignant neoplasms, and antineoplastic pharmacotherapy in multi-day episodes of care were reviewed.



Australian Consortium for Classification Development




Neoplasms

Changes to: Australian Coding Standards



Australian Consortium for Classification Development




Neoplasms


The following Australian Coding Standards have been revised:

- ACS 0044 *Chemotherapy*
- ACS 0222 *Lymphoma*
- ACS 0229 *Radiotherapy*
- ACS 0233 *Morphology*
- ACS 0234 *Contiguous Sites*
- ACS 0236 *Neoplasm Coding and Sequencing*

The following Australian Coding Standard has been retired:

- ACS 0218 *Lymphangitis Carcinomatosis*

 Australian Consortium for Classification Development




Neoplasms

ACS 0044 *Chemotherapy*

- ACS title amended to *Pharmacotherapy*
- Code title changes

Z54.2	Convalescence following pharmacotherapy Convalescence following chemotherapy	Z92.6	Personal history of pharmacotherapy for neoplastic disease
-------	---	-------	--
- Transmucosal and oral routes of administration has also been added to the ACS

 Australian Consortium for Classification Development



Neoplasms

Example 1:

A 31 year old lady presented with symptoms of abdominal pain and vomiting for one month along with a persistent dry cough and breathlessness.

High resolution CT revealed perionchovascular thickening of the subpleural interstitium with marked pleural effusion due to lymphangitis carcinomatosa associated with adenocarcinoma of unknown primary origin.



Australian Consortium for Classification Development



Neoplasms


Example 1 continued:

Assign:

- | | |
|---------|--|
| C78.0 | <i>Secondary malignant neoplasm of lung</i> |
| M8140/6 | <i>Adenocarcinoma, metastatic NOS</i> |
| C80.0 | <i>Malignant neoplasm, primary site unknown, so stated</i> |
| M8140/3 | <i>Adenocarcinoma NOS</i> |




Australian Consortium for Classification Development




Neoplasms

ACS 0234 *Contiguous sites*


ACS 0234 *Contiguous sites* has been amended to clarify that if a malignant neoplasm from a primary site spreads, this should be considered to be an expansion of the primary neoplasm and should not be classified as a separate primary or secondary neoplasm.


 Australian Consortium for Classification Development



Neoplasms

Contiguous site of the Breast – Breast Quadrants



RIGHT BREAST

LEFT BREAST




 Australian Consortium for Classification Development

Image Source: SEER Training Website





Neoplasms

Example 2:
A patient is admitted for excision of lesion of right breast at 6 o'clock. The lesion was excised under GA. The histopathology report revealed papillary carcinoma of the breast.

Assign:

C50.8	<i>Overlapping lesion of breast</i>
M8050/3	<i>Papillary carcinoma, primary</i>
31500-00 [1744]	<i>Excision of lesion of breast</i>
92514-99 [1910]	<i>General anaesthesia ASA 99</i>


 Australian Consortium for Classification Development




Neoplasms

ACS 0236 Neoplasm Coding and Sequencing



- 'malignancy' replaced with 'neoplasm'
- 'chemotherapy' replaced with 'pharmacotherapy'
- For metastases of primary neoplasm, assign a code for the metastatic site with appropriate morphology code, and a code for the primary neoplasm with its morphology
- Cross references added: ACS 0052 *Same-day endoscopy*, ACS 0237 *Recurrence of malignancy*, ACS 1204 *Plastic surgery* and ACS 2114 *Prophylactic surgery*
- The sequencing of primary and secondary neoplasm codes remain dependent on the treatment performed at each episode of care. Assign the principal diagnosis as per the criteria in ACS 0001 *Principal diagnosis*.

 Australian Consortium for Classification Development



Neoplasms

Changes to ICD-10-AM

Neoplasms

ICD-10-AM Tabular List

N90 **Other noninflammatory disorders of vulva and perineum**

Excludes: benign neoplasm of vulva (D28.0)
carcinoma in situ of vulva (D07.1)
current obstetric trauma (O70.-, O71.7–O71.8)
inflammation of vulva (N76.-)

N90.3 **Dysplasia of vulva, unspecified**
Vulval intraepithelial neoplasia (VIN):

- pagetoid type
- unclassified type


Use additional code (B97.7) to identify HPV (human papillomavirus), if applicable


Excludes: benign neoplasm of vulva (D28.0)
carcinoma in situ of vulva (D07.1)

ICD-10-AM Alphabetic Index

Dysplasia

- vulva NEC N90.3
- - mild (M8077/0) D28.0
- - moderate (M8077/2) D07.1
- - severe NEC (M8077/2) D07.1







Neoplasms

Example 3:
 A 23 year old female is admitted for biopsy of a suspicious lesion of vulva, under LA. Biopsy result reveals a high grade squamous (cell) intraepithelial lesion (HSIL), associated with Human Papillomavirus (HPV).

Assign:

D07.1	<i>Carcinoma in situ of vulva</i>
B97.7	<i>Papillomavirus as the cause of diseases classified to other chapters</i>
M8077/2	<i>Squamous intraepithelial neoplasia, high grade</i>
35615-00 [1291]	<i>Biopsy of vulva</i>


 Australian Consortium for Classification Development




Neoplasms

Atypical Small Acinar Proliferation (ASAP) of the prostate is now classified as D40.0 from lead term 'proliferation'

Proliferation of primary cutaneous CD30-positive T-cells (M9718/3) C86.6
[- atypical small acinar prostate \(ASAP\) \(M8550/1\) D40.0](#)
[- primary cutaneous CD30-positive T-cells \(M9718/3\) C86.6](#)

 Australian Consortium for Classification Development




Neoplasms


Example 4:
64 year old male admitted for TRUS biopsy of the prostate, under sedation. Histopathology returned a result of “atypical small acinar proliferation”.

Assign:

D40.0	<i>Neoplasm of uncertain or unknown behaviour, prostate</i>
M8550/1	<i>Acinar cell tumour</i>
37218-00 [1163]	<i>Needle biopsy of prostate or seminal vesicle</i>
92515-99 [1910]	<i>Sedation, ASA 99</i>




Australian Consortium for Classification Development




Neoplasms

Changes to ACHI



Australian Consortium for Classification Development




Neoplasms

Transarterial chemoembolisation (TACE)


TACE has been added to the Alphabetic Index.

Assign:

- 35321-05 **[768]** *Transcatheter embolisation of blood vessels, abdomen*
- 35317-02 **[741]** *Peripheral arterial or venous catheterisation with administration of other therapeutic agent*



Australian Consortium for Classification Development




Neoplasms

Example 5:


A 65 year old man was admitted for transarterial chemoembolisation (TACE) following diagnosis of a hepatocellular carcinoma. Therapeutic embolisation was performed with mixed lipiodol (20 mL) and doxorubicin (40 mg), followed by gelfoam pieces and cephalosporin at both hepatic arteries.

Assign Codes:

C22.0	<i>Liver cell carcinoma</i>
M8170/3	<i>Hepatocellular carcinoma</i>
35321-05 [768]	<i>Transcatheter embolisation of blood vessels, abdomen</i>
35317-02 [741]	<i>Peripheral arterial or venous catheterisation with administration of other therapeutic agent</i>



Australian Consortium for Classification Development



Neoplasms

T-cell therapy
(also known as Chimeric Antigen Receptor (CAR) therapy)

Stage 1
For collection of T-cells via apheresis, assign:


Apheresis


- therapeutic
- therapeutic leukopheresis 13750-01 [1892]

Stage 2
For infusion of the reengineered CAR T-cells (T-cell therapy), assign:

Administration

- type of agent
- white cells (donor leukocytes) 13706-04 [1893]

 Australian Consortium for Classification Development



Neoplasms

Prothrombin X


Administration


- type of agent
- prothrombin X 92061-00 [1893]

Albumex®

Administration

- type of agent
- albumin (Albumex) 92062-00 [1893]

 Australian Consortium for Classification Development



Neoplasms


Haemaccel®

Administration


- type of agent
- - Haemaccel 96166-19 [1920]

Non-essential modifiers have been added to 13942-02 [1922] to allow code assignment for connection or disconnection of a continuous ambulatory drug device delivery (CADD) system:

- device
- - drug delivery (CADD) ([connection](#)) ([disconnection](#)) (external infusion pump) [NEC 13942-02 \[1922\]](#)
- - - with loading of device 96209 [1920]
- - vascular access 13939-02 [1922]
- drug delivery device (CADD) ([connection](#)) ([disconnection](#)) (external infusion pump) [NEC 13942-02 \[1922\]](#)




Australian Consortium for Classification Development



Further information

For further detailed information regarding this revision please refer to the Reference to Changes Document provided in this Education Package.



Australian Consortium for Classification Development



Copyright

© Copyright Independent Hospital Pricing Authority 2019, Eleventh Edition.

ICD-10-AM is based upon the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* (ICD-10) 2016 Edition © World Health Organization. All rights reserved. Modified by permission for Australian Government purposes.

Whilst every reasonable care has been taken to ensure information accuracy within this publication, the ACCD and its staff make no warranty or guarantee that the information presented here is error free and will bear no responsibility for the results or consequences of the use of this material.

This work is copyright. It may be reproduced in whole or in part for study and training purposes subject to the inclusion of an acknowledgment of the source and no commercial usage or sale.

Reproduction for purposes other than those stated above requires the written permission of the IHPA (enquiries.ihpa@ihpa.gov.au).



Australian Consortium for Classification Development